Dow Chemical & Cambrex Collaborate to Manufacture Drug Solubility Solution
Cambrex and The Dow Chemical Company recently executed an agreement for Cambrex to contract manufacture Dow Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement.
This is the final step in building on the solubilization partnership that Dow and Bend Research announced in October 2012, and it will help Dow to commercially supply solubility enabling excipients. Construction has already begun on the new operational facility at Cambrex Karlskoga with commercial product availability set for year-end 2013.
“Dow’s polymer science and application expertise, coupled with Cambrex’s capabilities positions Dow for rapid entry into the market. The AFFINISOL product platform has excellent manufacturing flexibility to match the diverse excipients needs of our customers’ pipelines,” said Bob Maughon, Senior R&D Director for Dow.
“We are enthusiastic about bringing the first solution of our AFFINISOL product range to the market,” added Marc van Gerwen, Business Director for Dow. “This agreement demonstrates our ability to promptly address with material science the pharmaceutical industry’s most pressing need: advancing poorly soluble APIs to become therapeutically beneficial oral drug products.”
“We are proud to be part of this collaboration with Dow,” said Eric Neuffer, VP of Sales and Business Development for Cambrex. “This agreement between Dow and Cambrex further validates Cambrex’s commitment to finding solutions that offer our clients quality products and services to meet a market need. This has been a great partnership with both the Dow and Cambrex teams focused on achieving project goals and objectives in a timely manner.”
Cambrex Corporation is an innovative life sciences company that provides products, services, and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers APIs, advanced intermediates, and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances, and formulation of finished dosage form products. For more information, visit www.cambrex.com.
Total Page Views: 1191
